ANI Pharmaceuticals looks set to face tougher pushback on drug prices and reimbursements, leaving its growth and profits more exposed than many investors may expect. With the business leaning heavily on a few key therapies and a limited slate of new products, the big question is whether new launches and recent deals can offset tighter rules and rising compliance demands.Read more
ANI Pharmaceuticals is betting that more doctors will start using Cortrophin Gel in a wider range of conditions, helped by new product tweaks and a bigger rare-disease push. The big question is whether insurers, competition, and rising spending will squeeze the payoff just as the company leans harder on a few key products.Read more
Key Takeaways Strong momentum in rare disease and retina drug franchises, plus manufacturing efficiency, is fueling outsized revenue growth and expanding margins via product and market diversification. Domestic manufacturing focus and strategic acquisitions enhance supply chain resiliency and position ANI to capitalize on industry patent cliffs and emerging healthcare trends.Read more
No trending discussion available.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
